6589 Stock Overview
Operates as a contract development and manufacturing company in Taiwan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
EirGenix Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$79.10 |
| 52 Week High | NT$117.00 |
| 52 Week Low | NT$76.50 |
| Beta | 0.56 |
| 1 Month Change | -3.06% |
| 3 Month Change | -15.49% |
| 1 Year Change | -29.06% |
| 3 Year Change | -44.88% |
| 5 Year Change | 108.76% |
| Change since IPO | 75.82% |
Recent News & Updates
Shareholder Returns
| 6589 | TW Life Sciences | TW Market | |
|---|---|---|---|
| 7D | -1.2% | 0.5% | -0.8% |
| 1Y | -29.1% | -26.9% | 27.9% |
Return vs Industry: 6589 underperformed the TW Life Sciences industry which returned -26.8% over the past year.
Return vs Market: 6589 underperformed the TW Market which returned 29.2% over the past year.
Price Volatility
| 6589 volatility | |
|---|---|
| 6589 Average Weekly Movement | 3.2% |
| Life Sciences Industry Average Movement | 4.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in TW Market | 8.6% |
| 10% least volatile stocks in TW Market | 2.3% |
Stable Share Price: 6589 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6589's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | n/a | Lee-Cheng Liu | www.eirgenix.com |
EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and currently under Phase I stage; EG13074, indicated for the treatment of cancer and currently under Preclinical stage; TSY0110(EG12043), an antibody-drug conjugate, indicated for the treatment of cancer and currently under Preclinical stage; EG12021, Bevacizumab biosimilar, indicated for the treatment of cancer and currently under Preclinical stage; and EG62054, a biosimilar, currently under Preclinical stage.
EirGenix Inc. Fundamentals Summary
| 6589 fundamental statistics | |
|---|---|
| Market cap | NT$24.21b |
| Earnings (TTM) | -NT$815.74m |
| Revenue (TTM) | NT$1.03b |
23.6x
P/S Ratio-29.7x
P/E RatioIs 6589 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6589 income statement (TTM) | |
|---|---|
| Revenue | NT$1.03b |
| Cost of Revenue | NT$810.18m |
| Gross Profit | NT$215.84m |
| Other Expenses | NT$1.03b |
| Earnings | -NT$815.74m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.66 |
| Gross Margin | 21.04% |
| Net Profit Margin | -79.50% |
| Debt/Equity Ratio | 4.8% |
How did 6589 perform over the long term?
See historical performance and comparison